8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Apr 27, 2026·SEC
Pulse Biosciences, Inc.(PLSE)Earnings, Financials & Key Ratios
PLSE•NASDAQ
Price updated Jun 19, 2026
AboutPulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.Show more
- Revenue$350K
- EBITDA-$76M-37.7%
- Net Income-$73M-35.8%
- EPS (Diluted)-1.08-17.4%
- Gross Margin-360%
- EBITDA Margin-21676.57%
- Operating Margin-21982.57%
- Net Margin-20794.57%
- ROE-74.45%-10.6%
PLSE Key Insights
Pulse Biosciences, Inc. (PLSE) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 87 (top 13%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 15.4% in last year
- ✗Expensive at 21.4x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PLSE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PLSE Price & Volume
Pulse Biosciences, Inc. (PLSE) stock price & volume — 10-year historical chart
Loading chart...
PLSE Growth Metrics
Pulse Biosciences, Inc. (PLSE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-20.63%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-10.1%
Return on Capital
10 Years-88.26%
5 Years-92.97%
3 Years-69.17%
Last Year-73.07%
PLSE Recent Earnings
Pulse Biosciences, Inc. (PLSE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (91%)●Beat Revenue 2/12 qtrs (67%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.27+15.6%
$0.32
Rev
$400,000+60.0%
$250,000
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$0.26+1.9%
$0.27
Rev
$264,000+76.0%
$150,000
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.29+6.5%
$0.31
Rev
$86,000-61.8%
$225,000
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.28-7.7%
$0.26
Rev
—
$500,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.27vs $0.32+15.6% | $400,000vs $250,000+60.0% |
| Q1 2026 | Feb 19, 2026 | $0.26vs $0.27+1.9% | $264,000vs $150,000+76.0% |
| Q4 2025 | Nov 5, 2025 | $0.29vs $0.31+6.5% | $86,000vs $225,000-61.8% |
| Q3 2025 | Aug 12, 2025 | $0.28vs $0.26-7.7% | —vs $500,000 |
Based on last 12 quarters of dataView full earnings history →
PLSE Peer Comparison
Pulse Biosciences, Inc. (PLSE) competitors in Surgical and interventional devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ATEC | 1.33B | 8.81 | -9.18 | 24.95% | -21.07% | -443.09% | 17.21 | |
 ANAB | 2.48B | 57.51 | -125.02 | 157.01% | -11.53% | -24.49% | 0.38 | |
 INMD | 849.01M | 13.40 | 9.37 | -6.16% | 23.27% | 13.28% | 0.02 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 BSX | 67.31B | 45.29 | 23.35 | 19.87% | 14.4% | 12.4% | 0.51 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 |
Compare PLSE vs Peers
Pulse Biosciences, Inc. (PLSE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PLSE Income Statement
Pulse Biosciences, Inc. (PLSE) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 1.42M | 700K | 0 | 0 | 350K | 751K |
Revenue Growth % | - | - | - | - | - | -50.63% | -100% | - | - | - |
Cost of Goods Sold | 665K | 665K | 666K | 1.09M | 1.97M | 11.94M | 1.21M | 0 | 1.61M | 1.44M |
COGS % of Revenue | - | - | - | - | 138.79% | 1706.29% | - | - | 460% | - |
Gross Profit | -665K▲ 0% | -665K▲ 0.0% | -666K▼ 0.2% | -1.09M▼ 64.4% | -550K▲ 49.8% | -11.24M▼ 1944.4% | -1.21M▲ 89.3% | 0▲ 100.0% | -1.26M▲ 0% | -684K▲ 0% |
Gross Margin % | - | - | - | - | -38.79% | -1606.29% | - | - | -360% | -91.08% |
Gross Profit Growth % | 0% | 0% | -0.15% | -64.41% | 49.77% | -1944.36% | 89.27% | 100% | - | - |
Operating Expenses | 25.81M | 37.96M | 47.95M | 48.87M | 62.46M | 46.81M | 42.37M | 56.26M | 75.68M | 77.36M |
OpEx % of Revenue | - | - | - | - | 4405.08% | 6687.57% | - | - | 21622.57% | - |
Selling, General & Admin | 15.5M | 20.05M | 22.33M | 22.86M | 33.82M | 25.97M | 15.78M | 23.92M | 32.03M | 30.63M |
SG&A % of Revenue | - | - | - | - | 2385.33% | 3710.57% | - | - | 9151.14% | - |
Research & Development | 9.65M | 17.25M | 24.96M | 26.44M | 28.64M | 20.84M | 27.8M | 32.34M | 44.72M | 47M |
R&D % of Revenue | - | - | - | - | 2019.75% | 2977% | - | - | 12777.43% | - |
Other Operating Expenses | 665K | -28K | 666K | -430K | 0 | 0 | -1.21M | 0 | -1.07M | -267K |
Operating Income | -25.81M▲ 0% | -37.96M▼ 47.1% | -47.95M▼ 26.3% | -49.97M▼ 4.2% | -63.01M▼ 26.1% | -58.06M▲ 7.9% | -43.57M▲ 24.9% | -56.26M▼ 29.1% | -76.94M▼ 36.8% | -78.05M▲ 0% |
Operating Margin % | - | - | - | - | -4443.86% | -8293.86% | - | - | -21982.57% | -10392.14% |
Operating Income Growth % | -169.29% | -47.06% | -26.32% | -4.19% | -26.12% | 7.87% | 24.95% | -29.11% | -36.76% | - |
EBITDA | -24.81M | -36.65M | -46.79M | -48.87M | -61.87M | -56.7M | -42.37M | -55.08M | -75.87M | -76.69M |
EBITDA Margin % | - | - | - | - | -4363.05% | -8100.29% | - | - | -21676.57% | -10212.25% |
EBITDA Growth % | -181.1% | -47.72% | -27.67% | -4.44% | -26.6% | 8.35% | 25.28% | -30% | -37.74% | -22.66% |
D&A (Non-Cash Add-back) | 1M | 1.31M | 1.16M | 1.09M | 1.15M | 1.35M | 1.21M | 1.18M | 1.07M | 782K |
EBIT | -25.57M | -37.55M | -47.95M | -49.85M | -63.01M | -58.06M | -43.57M | -56.26M | -72.78M | -74.57M |
Net Interest Income | 0 | 0 | 983K | 114K | 0 | 0 | 1.36M | 2.67M | 4.21M | 3.55M |
Interest Income | 247K | 446K | 983K | 114K | 0 | 0 | 2.46M | 2.67M | 4.21M | 3.55M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 1.1M | 0 | 0 | 0 |
Other Income/Expense | 247K | 418K | 983K | 114K | -646K | -448K | 1.36M | 2.67M | 4.16M | 3.48M |
Pretax Income | -25.57M▲ 0% | -37.55M▼ 46.8% | -46.97M▼ 25.1% | -49.85M▼ 6.1% | -63.66M▼ 27.7% | -58.51M▲ 8.1% | -42.21M▲ 27.9% | -53.59M▼ 26.9% | -72.78M▼ 35.8% | -74.57M▲ 0% |
Pretax Margin % | - | - | - | - | -4489.42% | -8357.86% | - | - | -20794.57% | -9929.03% |
Income Tax | 0 | -28K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0.07% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -25.57M▲ 0% | -37.55M▼ 46.8% | -45.99M▼ 22.5% | -49.74M▼ 8.2% | -63.66M▼ 28.0% | -58.51M▲ 8.1% | -42.21M▲ 27.9% | -53.59M▼ 26.9% | -72.78M▼ 35.8% | -74.57M▲ 0% |
Net Margin % | - | - | - | - | -4489.42% | -8357.86% | - | - | -20794.57% | -9929.03% |
Net Income Growth % | -168.62% | -46.85% | -22.49% | -8.15% | -27.99% | 8.1% | 27.85% | -26.95% | -35.82% | -23.78% |
Net Income (Continuing) | -25.57M | -37.55M | -46.97M | -49.85M | -63.66M | -58.51M | -42.21M | -53.59M | -72.78M | -74.57M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.73▲ 0% | -2.20▼ 27.2% | -2.22▼ 0.9% | -2.14▲ 3.6% | -2.28▼ 6.5% | -1.72▲ 24.6% | -0.88▲ 48.8% | -0.92▼ 4.5% | -1.08▼ 17.4% | -1.10▲ 0% |
EPS Growth % | -101.16% | -27.17% | -0.91% | 3.6% | -6.54% | 24.56% | 48.84% | -4.55% | -17.39% | -10.1% |
EPS (Basic) | -1.73 | -2.20 | -2.22 | -2.14 | -2.28 | -1.72 | -0.88 | -0.92 | -1.08 | - |
Diluted Shares Outstanding | 14.75M | 17.08M | 20.75M | 23.25M | 27.96M | 33.94M | 48.04M | 58.4M | 67.4M | 67.79M |
Basic Shares Outstanding | 14.75M | 17.08M | 20.75M | 23.25M | 27.96M | 33.94M | 48.04M | 58.4M | 67.4M | 67.79M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
PLSE Balance Sheet
Pulse Biosciences, Inc. (PLSE) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 38.48M | 60.36M | 26.4M | 22.34M | 36.63M | 62.15M | 45.33M | 119.45M | 83.42M | 71.13M |
Cash & Short-Term Investments | 38.07M | 59.58M | 25.4M | 20.48M | 28.61M | 61.14M | 44.37M | 118.04M | 80.73M | 68.32M |
Cash Only | 3.39M | 51.1M | 6.9M | 12.46M | 28.61M | 61.14M | 44.37M | 118.04M | 80.73M | 68.32M |
Short-Term Investments | 34.68M | 8.48M | 18.5M | 8.01M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 61K | 0 | 0 | 0 | 274K | 157K |
Days Sales Outstanding | - | - | - | - | 15.7 | - | - | - | 285.74 | 54.19 |
Inventory | 0 | 0 | 0 | 0 | 5.82M | 0 | 0 | 0 | 136K | 206K |
Days Inventory Outstanding | - | - | - | - | 1.08K | - | - | - | 30.83 | 28.61 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 1.01M | 963K | 1.41M | 2.28M | 2.45M |
Total Non-Current Assets | 11.34M | 10.28M | 15.51M | 18.95M | 17.62M | 15.73M | 13.83M | 13.01M | 12.69M | 10.49M |
Property, Plant & Equipment | 2.57M | 2.17M | 7.68M | 11.92M | 11.25M | 10.02M | 8.78M | 8.32M | 7.06M | 6.72M |
Fixed Asset Turnover | - | - | - | - | 0.13x | 0.07x | - | - | 0.05x | 0.10x |
Goodwill | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M | 2.79M |
Intangible Assets | 5.88M | 5.21M | 4.55M | 3.88M | 3.22M | 2.55M | 1.89M | 1.22M | 575K | 408K |
Long-Term Investments | 0 | 0 | 0 | 0 | -3.25M | -2.73M | 1.89M | 0 | 0 | 0 |
Other Non-Current Assets | 101K | 101K | 494K | 365K | 365K | 365K | -1.52M | 677K | 691K | 575K |
Total Assets | 49.82M▲ 0% | 70.64M▲ 41.8% | 41.91M▼ 40.7% | 41.29M▼ 1.5% | 54.25M▲ 31.4% | 77.88M▲ 43.6% | 59.15M▼ 24.0% | 132.46M▲ 123.9% | 96.11M▼ 27.4% | 81.62M▲ 0% |
Asset Turnover | - | - | - | - | 0.03x | 0.01x | - | - | 0.00x | 0.01x |
Asset Growth % | 89.33% | 41.79% | -40.66% | -1.48% | 31.38% | 43.55% | -24.04% | 123.92% | -27.44% | 148.09% |
Total Current Liabilities | 2.21M | 3.11M | 4.46M | 7.58M | 8.52M | 5.98M | 6.71M | 10.05M | 7.92M | 9.8M |
Accounts Payable | 782K | 1.27M | 1.96M | 1.72M | 2.9M | 1.57M | 1.84M | 1.67M | 2.78M | 2.76M |
Days Payables Outstanding | 429.22 | 698.17 | 1.08K | 572.33 | 538.6 | 48.07 | 555.21 | - | 629.57 | 715.88 |
Short-Term Debt | 0 | 0 | 0 | 0 | 436K | 917K | 0 | 0 | 1.57M | 1.63M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 16K | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 397K | 415K | 234K | 3.32M | 1.46M | 50K | 3.2M | 1.2M | 1.6M | 5.41M |
Current Ratio | 17.39x | 19.42x | 5.92x | 2.95x | 4.30x | 10.39x | 6.76x | 11.88x | 10.53x | 7.26x |
Quick Ratio | 17.39x | 19.42x | 5.92x | 2.95x | 3.62x | 10.39x | 6.76x | 11.88x | 10.51x | 7.24x |
Cash Conversion Cycle | - | - | - | - | 557.27 | - | - | - | -312.99 | -633.08 |
Total Non-Current Liabilities | 1.61M | 1.2M | 6.72M | 10.81M | 10.04M | 74.14M | 8.09M | 7.54M | 7.54M | 5.53M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 65M | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 6.72M | 10.81M | 10.04M | 9.14M | 8.09M | 7.54M | 5.96M | 24.64M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.57M | 1.57M |
Other Non-Current Liabilities | 1.61M | 1.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.83M | 4.31M | 11.18M | 18.4M | 18.56M | 80.13M | 14.79M | 17.6M | 15.46M | 15.32M |
Total Debt | 0 | 0 | 6.72M | 11.36M | 11.25M | 75.96M | 9.14M | 8.9M | 7.53M | 7.16M |
Net Debt | -3.39M | -51.1M | -180K | -1.11M | -17.36M | 14.82M | -35.22M | -109.14M | -73.2M | -61.16M |
Debt / Equity | - | - | 0.22x | 0.50x | 0.32x | - | 0.21x | 0.08x | 0.09x | 0.11x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.09x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.80x |
Interest Coverage | - | - | - | - | - | - | -39.61x | - | - | - |
Total Equity | 45.99M▲ 0% | 66.33M▲ 44.2% | 30.74M▼ 53.7% | 22.89M▼ 25.5% | 35.69M▲ 55.9% | -2.25M▼ 106.3% | 44.36M▲ 2073.3% | 114.86M▲ 158.9% | 80.66M▼ 29.8% | 66.3M▲ 0% |
Equity Growth % | 81.81% | 44.22% | -53.66% | -25.52% | 55.89% | -106.3% | 2073.31% | 158.93% | -29.78% | 230.76% |
Book Value per Share | 3.12 | 3.88 | 1.48 | 0.98 | 1.28 | -0.07 | 0.92 | 1.97 | 1.20 | 0.98 |
Total Shareholders' Equity | 45.99M | 66.33M | 30.74M | 22.89M | 35.69M | -2.25M | 44.36M | 114.86M | 80.66M | 66.3M |
Common Stock | 84.22M | 142.05M | 21K | 25K | 29K | 37K | 55K | 66K | 68K | 68K |
Retained Earnings | -38.17M | -75.72M | -122.69M | -172.54M | -236.2M | -294.7M | -336.92M | -390.5M | -463.28M | -481.86M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -51K | -1K | 4K | -1K | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PLSE Cash Flow Statement
Pulse Biosciences, Inc. (PLSE) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -11.09M | -23.9M | -34.19M | -35.37M | -54.1M | -47.01M | -33.04M | -36.34M | -54.12M | -55.2M |
Operating CF Margin % | - | - | - | - | -3815.02% | -6716.14% | - | - | -15463.43% | - |
Operating CF Growth % | -37.71% | -115.53% | -43.06% | -3.45% | -52.97% | 13.1% | 29.72% | -9.99% | -48.92% | -166.35% |
Net Income | -25.57M | -37.55M | -46.97M | -49.85M | -63.66M | -58.51M | -42.21M | -53.59M | -72.78M | -74.57M |
Depreciation & Amortization | 1M | 1.31M | 1.16M | 1.09M | 1.15M | 1.35M | 1.21M | 1.18M | 1.07M | 1.04M |
Stock-Based Compensation | 10.93M | 12.34M | 11.29M | 10.07M | 14.6M | 5.19M | 7.18M | 13.59M | 21.46M | 17.69M |
Deferred Taxes | 26K | 28K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 2.12M | -112K | -521K | 116K | 13K | 8.66M | 13K | 6K | 1.15M | 1.8M |
Working Capital Changes | 408K | 113K | 860K | 3.2M | -6.2M | -3.72M | 768K | 2.47M | -5.02M | -1.16M |
Change in Receivables | 0 | 0 | 0 | 0 | -61K | 20K | 109K | 48K | -274K | -212K |
Change in Inventory | 0 | 0 | 0 | 0 | -5.82M | -2.65M | 0 | 0 | -136K | -176K |
Change in Payables | 517K | 490K | 646K | -266K | 1.16M | -1.3M | 263K | -201K | 1.13M | 272K |
Cash from Investing | -23M | 26.12M | -10.1M | 10.04M | 7.56M | -401K | -121K | -125K | -335K | -323K |
Capital Expenditures | -2.55M | -276K | -608K | -441K | -437K | -401K | -121K | -125K | -315K | -303K |
CapEx % of Revenue | - | - | - | - | 30.82% | 57.29% | - | - | 90% | 40.35% |
Acquisitions | 0 | 0 | 0 | -10.48M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -20.45M | 26.39M | 0 | 10.48M | 0 | 0 | 0 | 0 | -20K | -20K |
Cash from Financing | 35.38M | 45.5M | 82K | 30.89M | 62.69M | 79.94M | 16.39M | 110.14M | 17.15M | 4.56M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 407K | 65M | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 34.84M | 44.79M | 695K | 29.43M | -232K | 14.86M | 16.39M | 59.65M | 17.15M | 4.91M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 539K | 710K | -613K | 1.45M | 62.51M | 75K | -6K | 50.49M | 0 | -352K |
Net Change in Cash | 1.3M▲ 0% | 47.72M▲ 3579.0% | -44.2M▼ 192.6% | 5.56M▲ 112.6% | 16.15M▲ 190.3% | 32.52M▲ 101.4% | -16.77M▼ 151.6% | 73.67M▲ 539.2% | -37.3M▼ 150.6% | -50.96M▲ 0% |
Free Cash Flow | -13.64M▲ 0% | -24.17M▼ 77.2% | -34.79M▼ 43.9% | -35.81M▼ 2.9% | -54.53M▼ 52.3% | -47.41M▲ 13.1% | -33.16M▲ 30.1% | -36.47M▼ 10.0% | -54.44M▼ 49.3% | -55.5M▲ 0% |
FCF Margin % | - | - | - | - | -3845.84% | -6773.43% | - | - | -15553.43% | -7390.01% |
FCF Growth % | -68.06% | -77.24% | -43.94% | -2.91% | -52.3% | 13.06% | 30.06% | -9.97% | -49.27% | -37.89% |
FCF per Share | -0.92 | -1.42 | -1.68 | -1.54 | -1.95 | -1.40 | -0.69 | -0.62 | -0.81 | -0.82 |
FCF Conversion (FCF/Net Income) | 0.43x | 0.64x | 0.74x | 0.71x | 0.85x | 0.80x | 0.78x | 0.68x | 0.74x | 0.74x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PLSE Key Ratios
Pulse Biosciences, Inc. (PLSE) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -71.72% | -66.85% | -94.75% | -185.48% | -217.33% | -349.89% | -200.47% | -67.31% | -74.45% | -86.67% |
Return on Invested Capital (ROIC) | -58.83% | -98.45% | -157.1% | -143.18% | -235.64% | -281.87% | -301.08% | -567.83% | -876.1% | -962.01% |
Gross Margin | - | - | - | - | -38.79% | -1606.29% | - | - | -360% | -91.08% |
Net Margin | - | - | - | - | -4489.42% | -8357.86% | - | - | -20794.57% | -9929.03% |
Debt / Equity | - | - | 0.22x | 0.50x | 0.32x | - | 0.21x | 0.08x | 0.09x | 0.11x |
Interest Coverage | - | - | - | - | - | - | -39.61x | - | - | - |
FCF Conversion | 0.43x | 0.64x | 0.74x | 0.71x | 0.85x | 0.80x | 0.78x | 0.68x | 0.74x | 0.74x |
Revenue Growth | - | - | - | - | - | -50.63% | -100% | - | - | - |
Related:PLSE Dividend History·PLSE Revenue History·PLSE Price History·PLSE P/E History·PLSE Financial Ratios·PLSE Institutional Holders
PLSE SEC Filings & Documents
Pulse Biosciences, Inc. (PLSE) SEC filings — annual & quarterly reports (10-K, 10-Q)
PLSE Frequently Asked Questions
Pulse Biosciences, Inc. (PLSE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pulse Biosciences, Inc. (PLSE) reported $0.8M in revenue for fiscal year 2025.
Pulse Biosciences, Inc. (PLSE) grew revenue by 0.0% over the past year. Growth has been modest.
Pulse Biosciences, Inc. (PLSE) reported a net loss of $74.6M for fiscal year 2025.
Dividend & Returns
Pulse Biosciences, Inc. (PLSE) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.
Pulse Biosciences, Inc. (PLSE) had negative free cash flow of $55.5M in fiscal year 2025, likely due to heavy capital investments.